SEC Form 4 · accession 0000914190-18-000280
REGENERX BIOPHARMACEUTICALS INC · RGRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Allan L Goldstein
Director
Period of report
Jul 5, 2018
Accepted (ET)
Jul 9, 2018 · 4:17 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000707511
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 5, 2018 | C | 208,912 | $0.06 | A | 1,502,078 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Promissory Note (right to buy)F1 | $0.06 | Jul 5, 2018 | C | 208,912 | D | Jul 5, 2013 | Jul 4, 2018 | Common Stock | 208,912 | 0 | D |
Explanation of responses
- F1The Convertible Promissory Note in the principal amount of $10,000 accrued $2,534.72 in interest and both principal and interest were converted into 208,912 shares of common stock at a conversion price of $0.06 per share.